Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With Other Antiretroviral Agents in People Living With HIV

PHASE2CompletedINTERVENTIONAL
Enrollment

183

Participants

Timeline

Start Date

November 22, 2019

Primary Completion Date

October 5, 2021

Study Completion Date

September 19, 2023

Conditions
HIV-1-infection
Interventions
DRUG

Oral Lenacapavir

Tablets administered without regard to food

DRUG

F/TAF

Tablets administered without regard to food

DRUG

Subcutaneous Lenacapavir

Administered in the abdomen via subcutaneous injections

DRUG

TAF

Tablets administered without regard to food

DRUG

BIC

Tablets administered without regard to food

DRUG

B/F/TAF

Tablets administered without regard to food

Trial Locations (53)

10001

AHF-Midtown, New York

10103

Instituto Dominicano de Estudios Virológicos (IDEV), Santo Domingo

10467

Montefiore Medical Center, The Bronx

15212

Allegheny Health Network, Pittsburgh

20007

Georgetown University Hospital, Washington D.C.

20009

Whitman-Walker Institute, Inc., Washington D.C.

20017

Washington Health Institute, Washington D.C.

22003

Clinical Alliance for Research & Education - Infectious Diseases, LLC (CARE-ID), Annandale

27858

East Carolina University, The Brody School of Medicine, Greenville

28078

Rosedale Infectious Diseases, Huntersville

30033

Infectious Disease Specialists of Atlanta, Decatur

30309

Atlanta ID Group, PC, Atlanta

30912

August University Medical Center, Augusta

31201

Mercer University, Department of Internal Medicine, Macon

31401

Chatham County Health Department, Savannah

32720

Midland Florida Clinical Research Center, LLC, DeLand

33016

Floridian Clinical Research, Hialeah

33133

AHF-The Kinder Medical Group, Miami

33140

AIDS Healthcare Foundation - South Beach, Miami Beach

33401

Triple O Research Institute, P.A., West Palm Beach

33614

St. Joseph's Hospital Comprehensive Research Institute, Tampa

34982

Midway Immunology and Research Center, Ft. Pierce

38105

St. Jude Children's Research Hospital, Memphis

43210

The Ohio State University Medical Center, Columbus

44106

Case Clinical Research Site/University Hospitals Cleveland Medical Center, Cleveland

45267

University of Cincinnati, Cincinnati

46077

Indiana University Infectious Diseases Research, Indianapolis

48072

Be Well Medical Center, Berkley

48075

St. John Newland Medical Associates, Southfield

60613

Howard Brown Health Center, Chicago

60657

Northstar Healthcare, Chicago

64111

KC CARE Health Center, Kansas City

75208

Prism Health North Texas, Dallas

75246

North Texas Infectious Diseases Consultants, P.A., Dallas

75605

DCOL Center for Clinical Research, Longview

76104

Texas Centers for Infectious Disease Associates, Fort Worth

77098

The Crofoot Research Center, Inc., Houston

77401

St Hope Foundation, Bellaire

78705

Central Texas Clinical Research, Austin

80045

University of Colorado, Denver, University of Colorado Hospital, Aurora

80204

Denver Public Health, Denver

85004

Valleywise Community Health Center - McDowell, Phoenix

85015

Pueblo Family Physicians, Phoenix

90036

Ruane Clinical Research Group Inc, Los Angeles

90069

Mills Clinical Research at Men's Health Foundation, Los Angeles

92264

Eisenhower Health Center at Rimrock, Palm Springs

98104

Peter Shalit, M.D., Seattle

99204

MultiCare Rockwood HIV Critical Care Clinic, Spokane

06510

Yale University; School of Medicine, New Haven

32803-1851

Orlando Immunology Center, Orlando

00909-1711

Clinical Research Puerto Rico, San Juan

00909

HOPE Clinical Research, San Juan

00935

Proyecto ACTU, School of Medicine, University of Puerto Rico, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY